Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 March;52(1) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 March;52(1):37-49

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

 

  ADVANCES IN PET - PART II


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 March;52(1):37-49

language: English

Probe-guided localization of cancer deposits using [18F]fluorodeoxyglucose

Piert M., Carey J., Clinthorne N.

Division of Nuclear Medicine Department of Radiology University of Michigan, MI, USA


FULL TEXT  REPRINTS


In recent years, several probes have been developed to allow for the intraoperative detection of tumor tissue using [18F]fluorodeoxyglucose (FDG). Detector designs include high-energy γ and β probes, as well as combination devices with background rejection capabilities. Some laboratory prototypes and commercialized systems have demonstrated reasonable sensitivities for 511 keV photons and/or b particles emitted from 18F for in vivo use. This review focuses on the ability of these devices to detect tumor deposits in the low-contrast environment of the operating room. Important technical and biological factors that influence tumor-to-background contrast are discussed and potential future applications and developments are highlighted. In addition, we evaluate the limited data on absorbed doses resulting from [18F]FDG administration immediately prior to surgery that indicate acceptable levels of radiation exposure to operating room personnel.

top of page